| Item |
Medicine |
| Brand name |
OPDIVO |
| Generic name |
Nivolumab |
| Final report date |
03/27/2019 |
|
|
| Target population (1) |
Unresectable advanced or metastatic non-squamous, non-small cell lung cancer |
| Comparator |
Docetaxel |
| ICER |
JPY 15 million/QALY and over |
|
|
| Target population (2) |
Unresectable advanced or metastatic non-squamous, non-small cell lung cancer |
| Comparator |
Docetaxel |
| ICER |
JPY 15 million/QALY and over |
|
|
| Target population (3) |
Unresectable or metastatic renal cell cancer |
| Comparator |
Evelolimus |
| ICER |
JPY 15 million/QALY and over |
|
|
| Target population (4) |
Melanoma |
| Comparator |
Dacarbazine |
| ICER |
JPY 11.25 million/QALY and over, less than JPY 15 million/QALY |